Hematology News

The FDA granted rare pediatric disease designation to GBT440 for the treatment of sickle cell disease, according to the drug’s manufacturer.

The FDA accepted AMAG Pharmaceuticals’ submission to broaden the existing label for ferumoxytol to include the treatment of all adults with iron deficiency anemia who are intolerant to or have unsatisfactory response to oral iron.

Diffuse myocardial fibrosis, a common feature in sickle cell anemia, predicted the development of diastolic dysfunction, according to an observational study published in Blood.

ASH will honor several distinguished leaders in hematology at its annual meeting in December.

The FDA granted priority review to emicizumab for the treatment of adults, adolescents and children with hemophilia A with factor VIII inhibitors, according to the drug’s manufacturer.

Inferior vena cava filters have become an increasingly popular tool to reduce risk for recurrent pulmonary emboli since their introduction 50 years ago.

Click here to read the Cover Story, “‘Disconnect’ blamed for potential overuse of inferior vena cava filters.”

Extensive cancer screening for individuals who experience unprovoked venous thromboembolism initially may detect more cancer cases than a limited occult screening approach.

Patients with sickle cell anemia had an acute MI at an earlier age and an increased risk for hospital mortality compared with patients without sickle cell anemia, according to a study published in The American Journal of Cardiology.

Patients with newly diagnosed cancer have elevated risk for MI and stroke, particularly in the first 6 months after diagnosis, according to data published in the Journal of American College of Cardiology.